Immunohistochemical analysis of nuclear survivin expression in esophageal squamous cell carcinoma

Diseases of the Esophagus

Volumn 19, Issue 5, 2006, Pages 355-359

  Mega, S ^a   Miyamoto, M ^a   Li, L ^a   Kadoya, M ^a   Takahashi, R ^a   Hase, R ^a   Kaneko, H ^a   Shichinohe, T ^a   Kawarada, Y ^a   Itoh, T ^b   Morikawa, T ^a   Kondo, S ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Carcinogenesis; Esophageal squamous cell carcinoma; Immunohistochemistry; Prognosis; Survivin

Indexed keywords

SURVIVIN;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER PATIENT; CANCER THERAPY; CANCER TISSUE; CARCINOGENESIS; CARCINOMA CELL; CELL NUCLEUS; CONTROLLED STUDY; DRUG TARGETING; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCORING SYSTEM; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CELL NUCLEUS; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; RETROSPECTIVE STUDIES; TUMOR CELLS, CULTURED;

EID: 33748708850     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2006.00604.x     Document Type: Article

References (25)

1. Ando N, Iizuka T, Kakegawa T et al. A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: The Japan Clinical Oncology Group Study. J Thorac Cardiovasc Surg 1997; 114: 205-9.
2. Ando N, Ozawa S, Kitagawa Y, Shinozawa Y, Kitajima M. Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg 2000; 232: 225-32.
3. Collard J M, Otte J B, Fiasse R et al. Skeletonizing en bloc esophagectomy for cancer. Ann Surg 2001; 234: 25-32.
4. Ambrosini G, Adida C, Altieri D C. A novel anti-apoptotis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-21.
5. Altieri D C, Marchisio C. Survivin apoptosis: An interloper between cell death and cell proliferation in cancer. Lab Invest 1999; 79: 1327-33.
6. SalvesenBG S, Duckett C S. Apoptosis: IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 2002; 3: 401-10.
7. Kawasaki H, Altieri D C, Lu C D, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998; 58: 5071-4.
8. Lu C D, Altieri D C, Tanigawa N. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 1998; 58: 1808-12.
9. Ikeguchi M, Kaibara N. Survivin messenger RNA expression is a good prognostic biomarker for oesophageal carcinoma. Br J Cancer 2002; 87: 883-7.
10. Li F. Survivin study: What is the next wave? J Cell Physiol 2003; 197: 8-29.
11. Sobin L H, Wittekind Ch (eds) UICC TNM Classification of Malignant Tumors, 6th edn. New York: John Wiley 2002.
12. Grabowski P, Kühnel T, Mühr-Wilkenshoff F et al. Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. Br J Cancer 2003; 88: 115-9.
13. Muzio L L, Staibano S, Pannone G et al. Expression of the apoptosis inhibitor survivin in aggressive squamous cell carcinoma. Ex Mol Pathol 2001; 70: 249-54.
14. Altieri D C. Survivin and apoptosis control. Adv Cancer Res 2003; 88: 31-52.
15. Altieri D C. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3: 46-54.
16. Altieri D C. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 2001; 7: 542-7.
17. Hausladen D A, Wheeler M A, Altieri D C, Colberg J W, Weiss R M. Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guerin and mitomycin C on urinary survivin levels and outcome. J Urol 2003; 170: 230-4.
18. Li F, Ackermann E J, Bennett C F et al. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1999; 1: 461-6.
19. Carter B Z, Milella M, Altieri D C, Andreeff M. Cytokine-regulated expression of survivin in myeloid leukemia. Blood 2001; 97: 2784-90.
20. Lu C D, Altieri D C, Tanigawa N. Expression of a novel anti-apoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 1998; 58: 1808-12.
21. Ito T, Shiraki K, Sugimoto K et al. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 2000; 31: 1080-5.
22. Suzuki A, Ito T, Kawano H et al. Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death. Oncogene 2000; 19: 1346-53.
23. Garcia J F, Camacho F I, Molente M et al. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: Analyses using tissue microarrays. Blood 2003; 101: 681-9.
24. Koide N, Koike S, Adachi W, Amano J, Usuda N, Nagata T. Immunohistochemical expression of bcl-2 protein in squamous cell carcinoma and basaloid carcinoma of the esophagus. Surg Today 1997; 27: 685-91.
25. Shimoji H, Miyazato H, Nakachi A et al. Expression of p53, bcl-2, and bax as predictors of response to radiotherapy in esophageal cancer. Dis Esophagus 2000; 13: 185-90.